OBL Pharm is a Russian pharmaceutical company engaged in the development, production and promotion of modern and high-quality pharmaceuticals in accordance with GMP and ISO international standards.
The company produces more than 150 prescription and over-the-counter pharmaceuticals for gastroenterological, cardiologic, phlebologic and neurologic diseases, as well as for the treatment of acute and chronic pain, insomnia, for men’s health and more. The Company’s portfolio includes both innovative and generic pharmaceuticals.
The Company holds all the necessary licenses and certificates for producing pharmaceuticals and carrying out pharmaceutical activities:
OBL Pharm is a part of Alvansa Group since 2013, Gazprombank and the UFG Private Equity Investment Fund are its shareholders.